Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials

A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis

(2017) Càndid Villanueva et al.   HEPATOLOGY

Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy

(2017) Bogdan Procopet et al.   Gastroenterology Report

A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

(2016) Lung-Sheng Wu et al.   Cardiovascular Diabetology

Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review

(2016) Gaeun Kim et al.   Hepatology International

Pharmacologic Management of Portal Hypertension

(2014) Annalisa Berzigotti et al.   Clinics in Liver Disease

Liver cirrhosis

(2014) Emmanuel A Tsochatzis et al.   LANCET

Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes Mellitus

(2014) Jun Cheng et al.   JAMA Internal Medicine

Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway

(2013) Ze-Ping Hu et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Beta-blockers in portal hypertension: new developments and controversies

(2013) Dhiraj Tripathi et al.   LIVER INTERNATIONAL

Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic options

(2012) Josephine A. Grace et al.   CLINICAL SCIENCE

Comparative randomized study on efficacy of losartanversuspropranolol in lowering portal pressure in decompensated chronic liver disease

(2012) Ananta Kumar Agasti et al.   Journal of Digestive Diseases

Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome

(2012) Takuya Kishi et al.   JOURNAL OF HYPERTENSION

Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial

(2011) Hisashi Hidaka et al.   JOURNAL OF GASTROENTEROLOGY

Endothelial dysfunction in the regulation of cirrhosis and portal hypertension

(2011) Yasuko Iwakiri   LIVER INTERNATIONAL

Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis

(2010) Puneeta Tandon et al.   JOURNAL OF HEPATOLOGY

Management of Varices and Variceal Hemorrhage in Cirrhosis

(2010) Guadalupe Garcia-Tsao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Irbesartan Plus Low-Dose Propranolol Versus Low-Dose Propranolol Alone in Cirrhosis: A Placebo-Controlled, Double-Blind Study

(2008) Michael Schepke et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY